Clinical complete response (cCR)
No sign of tumour on examination, endoscopy, and MRI after treatment, without surgery to confirm it. It is the basis of organ-preservation strategies.
Defined by digital rectal exam, endoscopy (flat white scar), and MRI (TRG1) in rectal cancer; sustained cCR at 12 months is the primary endpoint of AZUR-1. Watch-and-wait after chemoradiation (OPRA, IWWD) and after immunotherapy (dostarlimab) preserve the rectum; regrowth is usually salvageable with surgery.
Pages like this
not linked directly; found by shared links- TrialCROSS
Shares CROSS chemoradiation → surgery → adjuvant nivolumab if residual disease, Organ preservation as the default after complete response in oesophageal cancer, SANO, Pathologic complete response (pCR).
- TrialNICHE-2
Shares Neoadjuvant checkpoint inhibitor → surgery (or no surgery) in dMMR colorectal cancer, Pathologic complete response (pCR), Colorectal cancer.
- PersonAndrea Cercek
Shares AZUR-1, Colorectal cancer.
- TrialCheckMate 577
Shares CROSS chemoradiation → surgery → adjuvant nivolumab if residual disease, Oesophageal cancer.
- TrialATOMIC (Alliance A021502)
Shares Neoadjuvant checkpoint inhibitor → surgery (or no surgery) in dMMR colorectal cancer, Colorectal cancer.
- ProductDostarlimab
Shares AZUR-1, Neoadjuvant checkpoint inhibitor → surgery (or no surgery) in dMMR colorectal cancer, Colorectal cancer.
- ProductFluorouracil (5-FU)
Shares Anal cancer (squamous cell carcinoma), Oesophageal cancer, Colorectal cancer.
- TermOesophagectomy
Shares SANO, Oesophageal cancer.